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Abstract
Genes encoding for isocitrate dehydrogenases 1 and 2, IDH1 and IDH2, are frequently mutated in
multiple types of human cancer. Mutations targeting IDH1 and IDH2 result in simultaneous loss
of their normal catalytic activity, the production of α-ketoglutarate (α-KG), and gain of a new
function, the production of 2-hydroxyglutarate (2–HG). 2-HG is structurally similar to α-KG, and
acts as an α-KG antagonist to competitively inhibit multiple α-KG-dependent dioxygenases,
including both lysine histone demethylases (KDM) and the ten-eleven translocation (TET) family
of DNA hydroxylases. Abnormal histone and DNA methylation are emerging as a common
feature of tumors with IDH1 and IDH2 mutations and may cause altered stem cell differentiation
and eventual tumorigenesis. Therapeutically, unique features of IDH1 and IDH2 mutations make
them good biomarkers and potential drug targets.
Introduction
Altered metabolic regulation in tumor cells was observed more than 80 years ago. Tumor
cells, despite having an increased uptake of glucose, produce much less ATP than expected
from complete oxidative phosphorylation and accumulate a significant amount of lactate.
(1–3). This phenomenon, representing arguably the first molecular phenotype characterized
in cancer, is commonly known as Warburg Effect. The Warburg Effect’s most notable
clinical application is in FDG-PET, where it provides the theoretical basis for the detection
of tumors because of their increased glucose uptake relative to surrounding normal tissues.
Despite its long history and broad clinical application, however, relatively little progress has
been made over past four decades in understanding how altered metabolic regulation
contributes to tumorigenesis. This is largely due to the fact that cancer research during this
period has focused on genetic mutations in human cancer which, until very recently, were
not known to include metabolic enzymes. The recent discovery of mutations targeting
metabolic genes in cancer has renewed interest in cancer metabolism. Eight genes: FH,
SDHA, SDHB, SDHC, SDHD, SDHAF2, IDH1 and IDH2, encoding for four different
metabolic enzymes: fumurate hydratase (FH), succinate dehydrogenase (SDH), isocitrate
dehydrogenase 1 and 2 (IDH1 and IDH2) are frequently mutated. These mutations are both
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will focus the discussion on the mechanisms and the translational research of IDH1 and
IDH2, two of the most frequently mutated metabolic genes in human cancer.
IDH1 and IDH2 genes are mutated in gliomas, acute myeloid leukemia
(AML), and multiple other types of human cancers
The mutation targeting IDH1 was first discovered in 2008 by a cancer genome project that
systematically sequenced 20,661 genes in 22 human glioblastoma multiforme (GBM)
samples and discovered 5 instances same heterozygous Arg132-to-His (R132H) point
mutation (5). This finding was quickly confirmed by multiple studies through directed
sequencing of IDH1 and its homologue IDH2 which cumulatively established that IDH1 or,
less frequently, IDH2 genes are mutated in more than 75% of grade 2 – 3 gliomas and
secondary glioblastomas (6–15). A separate cancer genome project in 2009 compared the
genomes from tumor and normal cells in an individual patient with AML and identified a
mutation in the IDH1 gene which was subsequently found in additional AML samples (16).
Further directed sequencing established that the IDH1 or IDH2 genes are mutated in close to
20% of AML (17–24). Following the discovery in glioma and AML, mutations targeting
IDH1 and IDH2 genes were found in multiple additional types of human tumors, including
thyroid carcinomas (16%) (25, 26), cartilaginous tumor (75%) (27–29), intrahepatic
cholangiocarcinoma (23%) (30, 31), as well as several other types of tumors at lower
frequency (31–34) (Table 1).
IDH1 and IDH2 mutations exhibit distinct biochemical and clinical features
Mutations targeting IDH1 and IDH2 in different types of tumors share four distinct
biochemical features. First, IDH1 and IDH2 mutations in tumors are predominantly somatic
and rarely germline (35). Second, all tumors with IDH1/2 mutations are heterozygous. This
is consistent with both a gain of function and dominant effect over the remaining wild-type
allele. Third, nearly all IDH1/2 mutations cause a single amino acid substitution, Arg132 in
IDH1 (to one of six amino acid residues—His, Cys, Leu, Ile, Ser, Gly and Val), or
corresponding Arg172 in IDH2 (to one of four different residues—Lys, Met, Gly and Trp),
and Arg140 in IDH2 to either Gln or Trp. These three residues are located in the enzymes’
active sites, suggesting a direct impact of mutation on the catalytic properties of the
enzymes. Infrequently IDH1 mutations also include R100A in adult glioma, and G97D in
colon cancer cell lines and a pediatric glioblastoma line (36). Lastly, IDH1 and IDH2
mutations occur in a mutually exclusive manner in most cases, indicating a common
underlying biochemical mechanism and physiological consequence. Only rarely, individual
tumors have been found to sustain mutations in both the IDH1 and IDH2 genes (8).
Mutations targeting IDH1 and IDH2 also exhibit three distinct clinical features. First, they
occur in a highly restricted tumor spectrum. For example, they occur frequently in grade 2-3
gliomas and secondary glioblastomas, but not in primary GBM. Similarly, they are
frequently found in cytogenetically normal AML, but not other sub-types of AML. This
pattern suggests that the contribution of IDH1/2 mutations to tumorigenesis may be linked to
cell fate determination at a specific stage of stem or progenitor cell differentiation. Second,
IDH1/2 mutations occur at an early stage of tumorigenesis, and represent the earliest known
mutation in glioma. This is consistent with the notion that IDH1/2 mutations may impair cell
fate determination and subsequent differentiation. Lastly, in glioma(13), AML (37) and
intrahepatic cholangiocarcinoma (37) where a sufficient number of samples have been
analyzed, IDH1 or IDH2 mutations alone or in combination with other gene mutations (in
the case of AML) are associated with better prognosis. These findings, together with results
showing that ectopic expression of tumor-derived mutant IDH1 reduces the proliferation of
established glioma cells in vitro (38, 39), suggest that mutant IDH enzymes, although
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promoting tumorigenesis in the long run, may also cause growth inhibition resulting from 2-
HG toxicity.
These unique properties of IDH1/2 mutations not only raise important mechanistic,
biological, and clinical questions about the role of this metabolic pathway in tumorigenesis,
but also provide a unique opportunity to develop a strategy for therapeutic intervention.
Mutant IDH1 and IDH2 lose their normal activity to produce α-KG and gain a
new activity producing 2-HG
The first biochemical alteration that was associated with tumor-derived IDH1 or IDH2
mutants was the loss of their normal activity in catalyzing the NADP+-dependent oxidative
decarboxylation of isocitrate into α-ketoglutarate (α-KG, also known as 2-oxyglutarate or
2OG) and NADPH (Figure 1)(13, 40). In cultured cells, ectopic expression of tumor-derived
IDH1 mutant resulted in inhibition of the activity of prolyl hydroxylase (PHD), a member of
the α-KG-dependent dioxygenase family of enzymes (see below), which can be restored by
feeding cells with cell-permeable α-KG(40). This finding provided early evidence linking
the mutation in IDH1 or IDH2 to the function of a specific metabolite, α-KG.
A subsequent study found that, surprisingly, the mutant IDH1 not only abolished its normal
activity, but also gained a new function: catalyzing the α-KG to D-2-hydroxyglutarate (D-2-
HG, also known as R-2-HG) (41) (Figure 1). Further studies found that all of the tumor-
derived IDH2 mutants targeting either Arg140 or Arg172 also gained this new activity (42–
44). In addition to glioma and AML, the accumulation of D-2-HG has been confirmed in
enchondroma (45), indicating a cell-autonomous nature to the 2-HG production and
accumulation in IDH1/2-mutated cells. Astonishingly, D-2-HG accumulates to as high as 5 -
35 µmol/g (or 5 - 35mM) in the case of gliomas. Taking advantage of these high metabolite
levels, efforts are currently underway to develop magnetic resonance spectroscopy (MRS)
techniques to non-invasively detect the accumulation of D-2-HG in glioma patients (46–50).
This MRS-based brain imaging for D-2-HG is still very experimental, and is not yet ready
for routine clinical application.
Beside mutant IDH1/2, there are several additional enzymes in mammalian cells, such as 2-
hydroxyglutarate dehydrogenase (2–HGDH), hydroxyacid-oxoacid transhydrogenase
(HOT), and L-malate dehydroxygenase (L-malDH), which are also involved in 2-HG
metabolism, suggesting the possibility that their alteration could lead to 2-HG accumulation
as well (51–54). L-2HG and D-2HG aciduria (L-2HGA and D-2HGA) are autosomal
recessive neurometabolic disorders which were first described in 1980. They are
characterized by the significant elevation (by 10 - 100 folds) of urinary levels of D-2-HG or
L-2-HG(55, 56). D-2HGA is rare, with symptoms including epilepsy, hypotonia and
psychomotor retardation. L-2HGA is more prevalent and severe, and mainly affects the
central nervous system in infancy leading to progressive hypotonia, tremors, epilepsy,
leukoencepalopathy, mental retardation, psychomotor regression and occasionally brain
tumors (57).
IDH1 and IDH2 enzymes produce NADPH and α-KG
The IDH family includes three distinct enzymes in human cells: IDH1, IDH2 and IDH3. All
the three enzymes catalyze the same enzymatic reaction: oxidative decarboxylation of
isocitrate to produce α-KG, but each has its own unique features (Figure 1). IDH1 is located
in the cytosol and the peroxisomes, while IDH2 and IDH3 are located in the mitochondria.
IDH1 and IDH2 use NADP+ while IDH3 uses NAD+ as electron acceptors to produce
NADPH or NADH, respectively. While both IDH1 and IDH2 form a homodimer, IDH3 is a
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heterotetrameric enzyme formed by two α subunits, one β subunit, and one γ subunit and is
the principle IDH enzyme involved in the tricarboxylic acid (TCA) cycle. Mutations have
thus far only been found to target either IDH1 or IDH2 genes in human tumors, but not
IDH3. The basis for this prevalence is not entirely clear, but likely relates to the facts that
loss of function of IDH3, unlike that of IDH1 and IDH2, may be detrimental to cell growth
because of disruption of the TCA cycle. Additionally, Arg132, which is conserved in both
IDH1 and IDH2 and is the principle site of mutation, is not conserved in any of the three
IDH3 subunits.
Two products of IDH1 and IDH2 enzymes, NADPH and α-KG, play broad functions in cell
regulation. NADPH is involved in many cellular processes including defense against
oxidative stress, fatty acid synthesis, and cholesterol biosynthesis. As reducing oxidative
stress and increasing fatty acid synthesis are required for cell division, NADPH is an
important metabolite for the proliferation of both normal and tumor cells. IDH1 mutation
was previously found to result in lowered NADPH tissue levels (58), although no difference
in NADPH levels was observed in another study (59). Whether reduced NAPDH production
by the mutations targeting IDH1/2 causes decreased cell proliferation, thus contributing to
relatively slower tumor growth, or is being compensated by the increased activity of other
NADPH producing enzymes has not been determined.
α-KG plays critical roles in four different metabolic and cellular pathways. First, α-KG is a
key intermediate in the TCA/Krebs Cycle for energy metabolism. Second, α-KG is an entry
point for several five-carbon amino acids (Arg, Glu, Gln, His and Pro) to enter the TCA by
GDH after they are first converted into glutamate. Metabolism of glutamate to α-KG is a
major step in anaplerosis whereby TCA cycle intermediates are replenished after being
extracted for biosynthesis. Third, α-KG can be reduced back to isocitrate and then citrate for
the eventual synthesis of acetyl CoA, the central precursor for fatty acid synthesis and
protein acetylation. Recent studies have shown that α-KG can be reductively carboxylated
by the NADPH-linked cytosolic IDH1 or mitochondrial IDH2 to form isocitrate which can
then be isomerized to citrate (60, 61) under hypoxic conditions (62). These findings support
the notion that IDH1 and IDH2 are bidirectional enzymes under physiological conditions
that can both produce and consume α-KG to meet cellular demands. Fourth, α-KG is used as
a co-substrate for multiple α-KG-dependent dioxygenases involved in the hydroxylation of
various protein and nucleic acid substrates (Figure 2). This last function of α-KG, although
less known, is emerging as the main target of IDH1 and IDH2 mutations in human tumors.
α-KG-dependent dioxygenases hydroxylate diverse substrates and regulate
many cellular pathways
Dioxygenases (also known sometimes as oxygen transferases) refer to the enzymes that
incorporate both atoms of molecular oxygen (O2) into their substrates. Dioxygenases whose
activity requires Fe(II) and α-KG as cofactors are often referred to as Fe(II)- and α-KG-
dependent dioxygenases. In the reactions catalyzed by these enzymes, both α-KG and O2
can be considered to be co-substrates with one oxygen atom being attached to a hydroxyl
group in the substrate (hydroxylation) and the other taken up by α-KG leading to the
decarboxylation of α-KG and subsequent release of carbon dioxide (CO2) and succinate
(Figure 3).
The first identified α-KG-dependent dioxygenase was collagen prolyl hydroxylase (CPH),
discovered in 1967 (63). After this pioneering work, the α-KG-dependent dioxygenases
have been established as a widely distributed and continuously expanding family. The most
notable new addition is the ten-eleven translocation (TET) family of DNA hydroxylases
(64). The α-KG-dependent dioxygenases are present in all living organisms and catalyze
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hydroxylation reactions on a diverse set of substrates. They are involved in various
pathways involving collagen, histones, and transcription factors, alkylated DNA and RNA,
lipids, antibiotics, and the recently discovered 5-methylcytosine of genomic DNA and 6-
methyadennine of RNA (65, 66) (Figure 3). It is estimated that there are more than 60 α-
KG-dependent dioxygenases in humans based on sequence homology at the active site (67).
As the result of such a broad spectrum of substrates, the change in the activity of α-KG-
dependent dioxygenases resulting from IDH1/2 mutation is expected to potentially affect
multiple cellular pathways.
2-HG is structurally similar to and acts as an antagonist of α-KG
The catalytic core of α-KG-dependent dioxygenases consists of a conserved double-stranded
β-helix (DSBH) fold (67, 68). In the active site of Fe(II)/α-KG-dependent dioxygenases, α-
KG uses two oxygen atoms from the α-keto carboxyl end—one from its C-1 carboxylate
and one from C-2 ketone—to coordinate Fe(II) and two oxygen atoms linked to C-5 at the
acetate end to interact with conserved residues in the dioxygenases. Both enantiomers of 2-
HG are similar in structure to α-KG with the exception of the oxidation state on C-2
whereby the 2-ketone group in α-KG is replaced by a hydroxyl group in 2-HG. This
suggests that 2-HG may act as a competitive antagonist of α-KG to interfere with the
function of α-KG-dependent dioxygenases (Figure 1). This hypothesis was experimentally
demonstrated for multiple α-KG-dependent dioxygenases, in particular histone lysine
demethylases (KDMs) and the TET family of DNA hydroxylases both in vitro and in vivo
(42, 69). In gliomas with IDH1 mutation, both histone and DNA methylation are higher than
those in gliomas with wild-type IDH1. Perhaps the most direct evidence supporting this
hypothesis was a structural analysis which showed 2-HG bonding to the catalytic core of α-
KG-dependent dioxygenases and adopted a nearly identical orientation as α-KG, thereby
preventing the binding of α-KG to the enzyme active site (42, 69).
α-KG-dependent histone and DNA demethylases are two main targets of
IDH mutations
Not all α-KG-dependent dioxygenases are expected to be inhibited equally by 2-HG. The
ones which have higher affinities with 2-HG would be more sensitive to the accumulation of
2-HG in IDH1/2 mutated cells. In fact, Chowdhury et al. found that D-2-HG inhibits
different α-KG-dependent dioxygenases in vitro with a wide range of potencies (69), with
histone H3K9 and H3K36 demethylase KDM4A/JMJD2A being the most sensitive (IC50 =
24 μM), followed by H3K9/H3K36 demethylase KDM4C/JMJD2C (79 μM), H3K36
demethylase KDM2A/FBXL11 (106 μM), DNA repair enzyme ALKBH2 (424 μM), FIH
(1.5 mM), prolyl hydroxylases (PHDs, 7.3 mM) and γ-butyrobetaine dioxygenase BBOX-1
(13 mM). This finding suggests that the KDM family of histone demethylases, which
includes as many as 32 distinct enzymes in human cells and controls nearly all histone
demethylation, is a major target of IDH1/2 mutation. This notion is supported by in vivo
studies in both cultured cells and in human tumors. The levels of multiple histone
methylations, including H3K4, H3K9, H3K27 and H3K79, were elevated in cells expressing
tumor-derived IDH1/2 mutant or treated with cell-permeable 2-HG and in glioma with
mutated IDH1 (42). More recent research confirmed these findings and showed further that
depletion of H3K9 demethylase KDM4C/JMJD2C blocked cell differentiation (70).
The second major target of IDH1/2 mutations is the TET family of DNA hydroxylases
which catalyze three- sequential oxidation reactions, converting 5-methlycytosine (5mC)
first to 5-hydroxymethylcytosine (5hmC), then to 5-formylcytosine (5fC), and finally to 5-
carboxylcytosine (5caC) which can then be converted to un-methylated cytosine by thymine
DNA glycosylase (TDG) (12, 71–73). Three lines of genetic evidence support TET DNA
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hydroxylases as being pathologically relevant targets of IDH1/2 mutations. First, promoter
DNA methylation profiling analysis has revealed that a subset of glioblastomas, known as
the proneural subgroup (74), is enriched for IDH1 mutation and displays hypermethylation
at a large number of loci (75) which is known as the glioma-CpG island methylator
phenotype (G-CIMP). These findings suggest a potential link between IDH1 mutation and
increased DNA methylation. Second, inactivating mutations of the TET2 gene were found in
about 22% of AML cases, notably occurring in a mutually exclusive manner with that of
IDH1/2 genes in AML (43). Third, ectopic expression of IDH1R132H mutant in immortalized
primary human astrocytes, a cell type from which glioblastoma is believed to develop,
induce extensive DNA hypermethylation and reshaped the methylome in a fashion that
mirrors the changes observed in IDH1-mutated low-grade gliomas (76), supporting the
notion that IDH1 mutation alone is sufficient to cause the hypermethylation phenotype.
Finally, direct biochemical evidence supporting TET as a target of IDH1/2 mutation is that
D-2-HG inhibits TET activity in vitro and that the inhibition can be overcome by the
addition of α-KG (42).
IDH1 and IDH2 mutations are good biomarkers
Four features make IDH1/2 mutations easily detectable, reliable, and specific biomarkers.
First, IDH1 and IDH2 mutations occur in a highly restricted tumor spectrum and cell type.
Second, nearly all tumor-derived mutations target IDH1 at a single residue, Arg132, and
IDH2 at two residues, Arg140 and Arg172, which are located in a single exon 4 and can be
simply identified through PCR-based amplification and sequencing using small amounts of
tumor samples (e.g. one section of paraffin embedded tissue or a few cells). Third,
antibodies specifically recognizing mutant IDH1R132H protein have been developed, making
it possible to identify IDH1 mutation through conventional immunohistochemistry (IHC)
(77, 78). Fourth, MRS-based brain imaging technology, although still experimental and not
yet ready for routine clinical application, has been developed that can non-invasively detect
the accumulation of 2-HG in glioma patients (46–50).
In brain tumors, IDH1/2 mutations occur frequently (>75%) in grade 2-3 gliomas and
secondary glioblastomas, but much less frequently in primary GBM and other brain tumors.
As such, IDH1/2 mutations can be used to distinguish between primary and secondary GBM
which are pathologically indistinguishable but clinically distinct entities with different
prognoses. In addition, other reports suggest that IDH1/2 mutation can be utilized to
distinguish distinguish oligodendroglioma from morphological mimics such as
dysembryoplastic neuroepithelial tumors (79), infiltrative gliomas from non-neoplastic
reactive gliosis (80, 81) or other non-infiltrative neoplasms like gangliogliomas(82), or
pilocytic astrocytomas from other astrocytomas (83). However, it remains to be proven
whether IDH1 mutation is a prognostic factor per se or a predictor of response to treatment.
One study noted that IDH1 mutation is closely linked to prognosis in grade 2 to 4 gliomas
(84), however, another recent study suggested that IDH mutation status may not have
significant prognostic impact in grade 2 gliomas (85). In leukemia, IDH1/2 mutations were
found frequently in cytogenetically normal adult AML, but not other sub-types of pediatric
AML. Mutation of IDH2 alone, but not IDH1, is associated with a slightly favorable
prognosis (86). Patients with co-occurring NPM1 and either IDH1 or IDH2 mutations have
significantly better overall survival (37). Similarly, in intrahepatic cholangiocarcinoma,
mutations in IDH1 or IDH2 were associated with longer overall survival and were
independently associated with a longer span of time to tumor recurrence after resection (30).
Efforts are currently underway to prospectively study the treatment responses in tumor
patients with IDH1/2 mutations and provide further therapeutic insights.
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Are mutant IDH1 and IDH2 good drug targets?
The question on whether mutant IDH1/2 is a good drug target can be more specifically
framed as to whether IDH1/2-mutated tumors are addicted to 2-HG. A unique feature of
IDH1/2 mutations is that mutants of IDH1/2 actively produce a new metabolite, 2-HG, that
does not have an apparent physiological function. Therefore, small molecules that
selectively inhibit the 2-HG producing activity of mutant IDH1/2 would expect to have a
marginally toxic effect towards normal cells. Given that multiple α-KG-dependent
dioxygenases are inhibited by 2-HG in IDH1/2-mutated cells, a sudden withdrawal of 2-HG,
if achieved, could conceivably cause a detrimental effect to the survival of IDH1/2-mutated
cells. However, the direct evidence showing 2-HG addiction by the IDH1/2-mutated tumor
cells has not been reported at present.
Conclusions and perspectives
Several critical questions concerning the mechanisms and therapeutic targeting of IDH1/2-
mutated tumors remain unanswered. First, what genetic alterations collaborate with IDH1/2
mutations in promoting tumorigenesis? Given its broad inhibitory activity towards multiple
α-KG-dependent dioxygenases, the accumulation of 2-HG is expected to be toxic to the
IDH1/2-mutated cells. In fact, ectopic expression of tumor-derived mutant IDH1 decreased
the proliferation of D54 glioblastoma cells while overexpression of wild-type IDH1
stimulated D54 cell proliferation(38). One hypothesis explaining the tumorigenic activity of
mutant IDH1/2 would be that there is an additional genetic alteration that offsets or
alleviates the toxicity of 2-HG. In low grade glioma and secondary GBM, p53 mutations co-
occur early and frequently with IDH1 mutation (87, 88). Furthermore, recurrent losses of
chromosomes 1p and 19q have long been observed to associate with the development of
glioma, in particular oligodendroglioma (87) (89)(Figure 4). Two poorly characterized
genes, human homolog of Drosophila capicua (CIC) located in chromosome 19q and far
upstream element binding protein (FUBP1) located on chromosome 1p, have recently been
identified as leading candidates for the 1p and 19q tumor suppressor genes which are
mutated in an almost exclusive co-occurring manner with the IDH1/2 mutation (90–92). In
AML, IDH1 and IDH2 genes are most frequently co-mutated with nucleophosmin NPM1
gene, followed by DNA (cytosine-5)-methyltransferase 3A (DNMT3A) (37, 93–95).
Whether p53, CIC, FUBP1, NPM1, and DNMT3A mutations collaborate with IDH1/2
mutation remain to be determined.
Second, what are the downstream target genes of IDH1/2 mutation? In AML, mutations
targeting IDH1/2 and TET2 occur mutual exclusively (43), suggesting that, genetically,
IDH1/2 and TET2 may function in the same, linear IDH-TET pathway. This hypothesis was
supported by the finding that co-expression of wild-type and mutants of IDH1/2 resulted in
the stimulation and inhibition of TET activity, respectively, in cultured cells and that 2-HG
directly inhibited TET activity in vitro (42). The downstream targets of the IDH-TET
pathway have not been identified. There are two competing hypotheses concerning the
nature of the IDH-TET targets. One possibility is that a specific small set of genes, yet to be
identified, are normally activated by TET-mediated DNA demethylation and control the fate
of stem and progenitor cell differentiation. Inhibition of TET activity, by either mutation in a
TET gene or the inhibition of TET activity in IDH1/2-mutated cells alters their expression
and consequently restricts cellular differentiation. Alternatively, impairment of the IDH-
TET pathway may not selectively impede the expression of a small group of genes to
contribute tumorigenesis. Rather, DNA and histone methylation are altered widely in
IDH1/2 and TET2 mutated cells which increases epigenetic plasticity analogously to the
case of increased mutation rates and genomic plasticity in cells with impaired DNA repair
pathways. Subsequent selection of cells which have acquired proliferative and survival
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advantages, in a context-dependent manner, would lead to clonal expansion and eventual
tumorigenesis.
Third and urgently, mouse models for mutant IDH1/2, whether transgenic, xenograft or
ultimately knock-in IDH1/2 mutant mice, are not only needed to obtain direct genetic
evidence for the oncogenic activity of 2-HG, but more importantly for testing the effects of
small molecule inhibitors of mutant IDH1/2. The challenges of generating the IDH1/2
mouse model likely reflect the strong toxicity of 2-HG produced by the tumor-derived
mutant IDH1/2 that may severely block normal mouse development. This is also reflected in
the fact that despite the establishments of many cell lines from glioma, AML,
chondrosarcoma, and thyroid carcinomas, only one, HT1080 chondrosarcoma (reclassified
by the Wellcome Trust Sanger Institute from previously fibrosarcoma), has been found to
contain a mutation in IDH1 (R132C). Compounding the difficulty is the possibility that
mutant IDH1/2 alone may not be sufficient to cause tumorigenesis and combination with a
yet-to-be identified collaborating genetic mutation may be necessary. Recent isolation of a
glioma stem cell line, BT142, containing heterozygous IDH1R132H mutation and
establishment of a BT142 orthotopic xenograft mouse provide the first mouse model for
investigating the oncogenic activity of 2-HG (96). More recently, haematopoietic and
myeloid-specific conditional IDH1R132H-knock-in mice were generated (97), which,
although not developing spontaneous tumors, are characterized with induction of a
leukaemic DNA methylation signature. The availability of these mouse models will advance
our understanding of the mechanistic links between IDH1 mutations and tumorigenesis and
develop therapeutics against IDH1/2-mutated tumors.
In conclusion, the discovery and subsequent investigation of IDH1/2 mutations in tumors
have renewed interest into the research of tumor metabolism, identified a good biomarker
for early detection and prognosis of several types of tumors, and led to the elucidation of the
IDH-TET pathway in the epigenetic control of cell differentiation and tumor suppression.
The extensive efforts that are currently underway should lead to a better understanding of
the role of altered metabolic enzymes and metabolites in tumorigenesis, and novel strategies
for therapeutic intervention in IDH1/2-mutated tumors.
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Figure 1. Chemical reactions catalyzed by the wild-type IDH enzymes and tumor-derived
mutants IDH1 and IDH2
The only structural difference between α-KG and D-2-HG is the replacement of the 2-
ketone group in α-KG by a hydroxyl group in 2-HG and is indicated by red color.
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Figure 2. Production and utilization of α-KG in human cells
Four enzymes—IDH1, IDH2, IDH3 and GDH—can produce α-KG, which is used for four
separate pathways: TCA cycle, anaplerosis, fatty acid synthesis and protein and nucleic acid
hydroxylation. Pink colored arrows indicate reducing reactions catalyzed by either IDH1 or
IDH2.
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Figure 3. α-KG-dependent dixoygenases hydroxylate diverse substrates
Greater than 60 α-KG-dependent dixoygenases are estimated to be present in human cells.
They hydroxylate many different substrates, including proteins, DNA and RNA.
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Figure 4. IDH1/2 mutations inhibit both histone and DNA demethylation and alter epigenetic
regulation
Tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG
antagonist, 2-HG, leading to the inhibition of both α-KG-dependent histone lysine
demethylases (KDMs) and the TET family of DNA hydroxylases. These inhibitions alter the
epigenetic control of stem and progenitor cell differentiation.
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